Integra LifeSciences delivered a strong third quarter in 2025 with total revenues of $402.1 million, marking a 5.6% increase year-over-year. The company achieved significant profitability improvements, with adjusted EPS rising to $0.54 from $0.41 in the prior year, and adjusted EBITDA reaching $78.5 million. Despite some supply interruptions, demand remained healthy across its portfolio, and strategic initiatives to strengthen the supply chain and quality management system are progressing.
Total revenues for Q3 2025 reached $402.1 million, an increase of 5.6% on a reported basis compared to the prior year.
GAAP earnings per diluted share improved to $(0.07) from $(0.14) in the prior year, while adjusted earnings per diluted share increased to $0.54 from $0.41.
Adjusted EBITDA for the quarter was $78.5 million, representing 19.5% of revenue, up from $61.8 million (16.2% of revenue) in Q3 2024.
The company successfully relaunched PriMatrix® and Durepair® ahead of schedule through a dual sourcing supply strategy and is making progress on its Compliance Master Plan.
Integra LifeSciences is revising its 2025 guidance to reflect third-quarter revenue and updated assumptions for the fourth quarter. For Q4 2025, the company expects revenues between $420 million and $440 million and adjusted EPS in the range of $0.79 to $0.84 per share. The full-year 2025 revenue guidance is updated to $1.620 billion to $1.640 billion, with full-year adjusted EPS expected between $2.19 and $2.24 per share.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance